90Y-SIRT as Conversion Therapy for Unresectable Hepatocellular Carcinoma
Efficacy and Long-Term Outcomes of Yttrium-90 Treatment as Conversion Therapy for Unresectable Hepatocellular Carcinoma: A Multicenter Cohort Study
This multicenter observational study will evaluate long-term outcomes in patients with initially unresectable hepatocellular carcinoma who undergo curative-intent hepatectomy after conversion therapy. The conversion therapy is based on either yttrium-90 selective internal radiation therapy or transarterial chemoembolization. The study includes a retrospective cohort and a prospective observational cohort. The primary outcome is recurrence-free survival after surgery. Overall survival, postoperative pathological features, and perioperative outcomes will also be compared between the two groups.
調査の概要
状態
条件
詳細な説明
This study includes both retrospective and prospective components. The retrospective cohort will include eligible patients who previously underwent curative-intent hepatectomy after 90Y-SIRT-based or TACE-based conversion therapy. The prospective observational cohort will consecutively enroll eligible patients after curative-intent hepatectomy and follow them prospectively for postoperative outcomes.
研究の種類
入学 (推定)
連絡先と場所
研究連絡先
- 名前:Zheyu Zhou
- 電話番号:+86 18851092739
- メール:zzys02910@btch.edu.cn
研究場所
-
-
Beijing Municipality
-
Beijing、Beijing Municipality、中国、102218
- Beijing Tsinghua Changgung Hospital
-
コンタクト:
- Lin Zhang
- 電話番号:+86 15699793366
- メール:zla02285@btch.edu.cn
-
-
Chongqing Municipality
-
Chongqing、Chongqing Municipality、中国、400038
- Southwest Hospital, Army Medical University
-
コンタクト:
- Hui Zhang
- 電話番号:+86 02368754000
- メール:13637912611@163.com
-
-
Fujian
-
Fuzhou、Fujian、中国、350025
- Mengchao Hepatobiliary Hospital of Fujian Medical University
-
コンタクト:
- Wuhua Guo
- 電話番号:+86 059188110232
- メール:guowuhua@aliyun.com
-
-
Guangdong
-
Guangzhou、Guangdong、中国、510630
- The First Affiliated Hospital of Jinan University
-
コンタクト:
- Chengzhi Li
- 電話番号:+86 02038688888
- メール:lichengzhi@jnu.edu.cn
-
-
Liaoning
-
Shenyang、Liaoning、中国、110001
- The First Hospital of China Medical University
-
コンタクト:
- Haibo Shao
- 電話番号:+86 02483283333
- メール:haiboshao@aliyun.com
-
-
Shaanxi
-
Xi'an、Shaanxi、中国、710061
- The First Affiliated Hospital of Xi'an Jiaotong University
-
コンタクト:
- Xin Zheng
- 電話番号:+86 02985323112
- メール:xin.zheng.xjtu@gmail.com
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
The study population consists of patients with initially unresectable HCC treated at participating centers who undergo curative-intent hepatectomy after 90Y-SIRT-based or TACE-based conversion therapy. All consecutive patients meeting the predefined eligibility criteria will be included. Patients identified from historical records will form the retrospective cohort, while patients enrolled after study initiation will form the prospective observational cohort.
説明
Inclusion Criteria:
- Initially unresectable primary liver cancer.
- Underwent curative-intent hepatectomy following conversion therapy based on 90Y-SIRT or TACE.
- Postoperative histopathological examination confirmed HCC.
Exclusion Criteria:
- Received conversion therapy based on other locoregional treatments, such as hepatic arterial infusion chemotherapy (HAIC) or external beam radiotherapy (EBRT).
- Presence of extrahepatic metastasis prior to curative-intent hepatectomy.
- Postoperative histopathological diagnosis of intrahepatic cholangiocarcinoma (ICC) or combined hepatocellular-cholangiocarcinoma (cHCC-CCA).
- Failure to achieve R0 resection.
- Incomplete clinical data.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 観測モデル:COHORT
- 時間の展望:OTHER
コホートと介入
グループ/コホート |
|---|
|
90Y-SIRT-Based Conversion Therapy Group
Patients with initially unresectable hepatocellular carcinoma who received conversion therapy based on yttrium-90 selective internal radiation therapy (90Y-SIRT) and subsequently underwent curative-intent hepatectomy after being deemed resectable. |
|
TACE-Based Conversion Therapy Group
Patients with initially unresectable hepatocellular carcinoma who received conversion therapy based on transarterial chemoembolization (TACE) and subsequently underwent curative-intent hepatectomy after being deemed resectable. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
時間枠 |
|---|---|
|
Postoperative recurrence-free survival (RFS)
時間枠:From the date of curative-intent hepatectomy until the first tumor recurrence, death, or last follow-up, up to 5 years.
|
From the date of curative-intent hepatectomy until the first tumor recurrence, death, or last follow-up, up to 5 years.
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Postoperative overall survival (OS)
時間枠:From the date of curative-intent hepatectomy until death or last follow-up, up to 10 years.
|
From the date of curative-intent hepatectomy until death or last follow-up, up to 10 years.
|
|
|
Pathological complete response (pCR) rate
時間枠:Immediately after curative-intent hepatectomy.
|
pCR is defined as the absence of residual viable tumor cells in the resected specimens. The pCR rate is calculated as the proportion of patients achieving pCR among all patients with evaluable postoperative histopathological assessments. |
Immediately after curative-intent hepatectomy.
|
|
Major pathological response (MPR) rate
時間枠:Immediately after curative-intent hepatectomy.
|
MPR is defined as ≤10% residual viable tumor cells in the resected specimens. The MPR rate is calculated as the proportion of patients achieving MPR among all patients with evaluable postoperative histopathological assessments. |
Immediately after curative-intent hepatectomy.
|
|
Microvascular invasion (MVI) positivity rate
時間枠:Immediately after curative-intent hepatectomy.
|
Immediately after curative-intent hepatectomy.
|
|
|
Satellite nodule positivity rate
時間枠:Immediately after curative-intent hepatectomy.
|
Immediately after curative-intent hepatectomy.
|
|
|
Postoperative complication rate
時間枠:Perioperatively, from curative-intent hepatectomy through hospital discharge.
|
The occurrence and type of postoperative complications will be recorded, and their severity will be graded according to the Clavien-Dindo classification. Bile leakage and post-hepatectomy liver failure (PHLF) will also be graded according to the ISGLS criteria. |
Perioperatively, from curative-intent hepatectomy through hospital discharge.
|
その他の成果指標
結果測定 |
時間枠 |
|---|---|
|
Percentage change in tumor markers
時間枠:From baseline before conversion therapy to the preoperative assessment before curative-intent hepatectomy.
|
From baseline before conversion therapy to the preoperative assessment before curative-intent hepatectomy.
|
|
Percentage change in maximum tumor diameter
時間枠:From baseline before conversion therapy to the preoperative assessment before curative-intent hepatectomy.
|
From baseline before conversion therapy to the preoperative assessment before curative-intent hepatectomy.
|
協力者と研究者
捜査官
- 主任研究者:Lin Zhang、Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua Medicine, Tsinghua University, Beijing, China
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
- KX26-0904-0317
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
De-identified IPD underlying the published results may be made available upon reasonable request after publication, subject to approval by the principal investigator and applicable ethical and institutional requirements.
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。